By Sindhu Sundar ( March 8, 2016, 9:15 PM EST) -- The FDA this week chided a New York-based device maker for selling infusion pumps without premarket approval for so-called class III medical devices considered to pose the highest risk. The agency also continued to scrutinize weaknesses in medical providers' oversight of clinical trials, this time targeting a hospital in NYC over an internal board meeting, and slammed two dietary supplement makers — including one that touts seaweed as an HIV treatment — for making wild claims about their products' healing powers. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.